ERBB2 and endometrial cancer: Mechanistically, ICIs plus PARP inhibitors such as olaparib, which activates the cGAS/STING pathway in tumor cells, leading to dendritic cell priming and enhanced CD8+ T-cell recruitment (54, 55); Moreover, HER2 amplification occurs more frequently in p53abn endometrial cancers than in other molecular subtypes, affecting up to 25% of cases (68).